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Abstract
Objective: Regular screening and follow-up is an important key to cervical cancer prevention; however, screening inevitably
detects mild or borderline abnormalities that would never progress to a more severe stage. We analysed the cumulative
probability and recurrence of cervical abnormalities in the Finnish organized screening programme during a 22-year follow-up.
Methods: Screening histories were collected for 364,487 women born between 1950 and 1965. Data consisted of 1 207,017
routine screens and 88,143 follow-up screens between 1991 and 2012. Probabilities of cervical abnormalities by age were
estimated using logistic regression and generalized estimating equations methodology.
Results: The probability of experiencing any abnormality at least once at ages 30–64 was 34.0% (95% confidence interval [CI]:
33.3–34.6%). Probability was 5.4% (95% CI: 5.0–5.8%) for results warranting referral and 2.2% (95% CI: 2.0–2.4%) for results
with histologically confirmed findings. Previous occurrences were associated with an increased risk of detecting new ones,
specifically in older women.
Conclusion: A considerable proportion of women experience at least one abnormal screening result during their lifetime, and
yet very few eventually develop an actual precancerous lesion. Re-evaluation of diagnostic criteria concerning mild abnormalities
might improve the balance of harms and benefits of screening. Special monitoring of women with recurrent abnormalities
especially at older ages may also be needed.
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Introduction
Only a small proportion of mild cervical abnormalities
eventually lead to severe disease. There is evidence that
they are likely to heal spontaneously, especially among
younger women.1–3 The lifetime cumulative probability
of borderline cervical abnormalities has been studied in
few population-based studies. A study by Raffle et al.4
estimated that the lifetime risk of abnormal cytology
could be as high as 40%. Detection of cervical abnormal-
ities that would never progress to cancer may result in
overtreatment, physical and psychological distress, and
increased healthcare costs.5–7 Cross-sectional detection
rates, as well as the number of lifetime screening rounds,
vary greatly between different programmes.8 Thus vari-
ation in the cumulative risk of abnormal cytology may
also be high. In Finland, the national recommendation
is to invite all women aged 30–60 for screening every
5 years. All municipalities follow this policy, and some
also invite women aged 25 and 65. Consequently, a
woman may go through up to seven or, in some regions,
nine routine screens during her lifetime. The purpose
of this study was to determine the cumulative probability
of having cervical abnormalities at ages 30–64 in
organized screening. Our main interest was in the differ-
ence between borderline and more severe abnormalities.
We also analysed whether previous abnormalities had an
increasing effect on the risk of detecting new ones. Our
study highlights the harms experienced by screened
women and points out the potential need for improvement
in the diagnostic criteria.
Methods
Study population and data source
The Finnish cervical cancer screening programme intro-
duced in 1963 achieved a national coverage by the early
1970s.9 In addition to the 5-yearly routine screen,
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a follow-up test is recommended after 1–2 years if border-
line cervical abnormalities are detected, or if the woman
reports signs of symptoms such as bleeding or abnormal
vaginal discharge. If borderline abnormalities persist in
the follow-up test, referral for colposcopy and biopsy
are recommended. Referral is also recommended if a
clearly positive cytology result is detected, either in pri-
mary or follow-up screening. The Mass Screening
Registry of the Finnish Cancer Registry contains complete
data on invitations, screening tests, and diagnostic find-
ings in the organized programme since 1991. Screening
histories between 1991 and 2012 were collected for all
invited women, consisting of 3.6 million routine screens
among 1.5 million women. In addition there were around
230,000 follow-up screens. To utilize the longest possible
screening history of the invited women, cumulative prob-
abilities were estimated from cohorts of subjects who had
entered the follow-up between 1991 and 1995 while aged
30, 35, or 40, i.e. women born between 1951 and 1965.
Each cohort had 4–5 routine screens during the follow-up,
and altogether these cohorts had comprehensive data with
1.2 million routine screens and 88,000 follow-up screens
among 360,000 women. Municipalities inviting women
aged 25 were excluded, so that the youngest cohort aged
30 at baseline included only women being screened for the
first time, as our primary interest was in the national rec-
ommended target ages for screening. Municipalities are
obliged to invite all target-aged women to screening.
However, some routine screening invitations might not
have been sent regularly if a municipality did not invite
all target groups with a 5-yearly interval, or if women had
moved within or outside the country.
Measures and definitions
Conventional cytology is used as the primary screening
test in the Finnish programme. A screening result was
considered borderline if Pap class was II indicating react-
ive changes or atypical squamous intraepithelial lesion
with undetermined significance (ASC-US) in Bethesda
2001, or if HPV-test was positive and the reflex cytology
triage did not indicate a referral.10 Low-grade squamous
intraepithelial lesion or worse (LSILþ) led to a referral to
colposcopy examination, where potential cervical intrae-
pithelial neoplasia (CIN 1þ) was histologically confirmed.
We conducted the analysis by looking at 5-year screening
rounds. A screening round begins from an age-based rou-
tine screen and continues with possible follow-up screens
during the next 4 years, or until the next routine screen.
Three different outcomes were examined: (i) any abnor-
mality (borderline or more severe), (ii) referral to colpos-
copy and biopsy, and (iii) any histologically confirmed
finding (CIN 1 or more severe result) among the referred
women. Categories were overlapping, and thus women
with CIN 1 might also have a borderline finding and/or
a referral to colposcopy. The most severe result of a
screening round was treated as the outcome, detected
either by routine or follow-up screening. By comparing
the cumulative probabilities of the outcomes, we aimed
to determine the risk of borderline results without more
severe diagnoses and the risk of referrals without a histo-
logical confirmation in the colposcopy examinations (false
positives).
Statistical analysis
The probability of any abnormality by age was estimated
using logistic regression. A longitudinal approach allowed
the same individual to have multiple measurements in the
data. Generalized Estimating Equation (GEE) method
with an independent correlation structure was used to
account for individual-level correlation.11,12 The GEE
model was chosen because it is considered appropriate
for the analysis of discrete time points (here screening
age categories).13 First, analysis was conducted separately
for the three cohorts (aged 30, 35, and 40 at entry). The
model included attained age in 5-year age groups, number
of previous abnormal results (classified as 0, 1, or 2þ), and
irregular invitation and attendance history (classified as
0 up to the first irregularity and 1 afterwards) as time-
varying categorical covariates. By including the number
of previous abnormalities as a covariate, we were able to
estimate the association between previous abnormalities
and the risk of subsequent ones, i.e. whether the abnorm-
alities in the data accumulated to the same women. We
adjusted for irregular invitation and attendance history to
reduce bias due to different attendance patterns. A joint
model was then estimated by combining all three cohorts.
The joint model also included a cohort indicator as a cat-
egorical variable, and its interaction with the number of
previous abnormalities, to allow previous abnormalities to
have a different effect on the outcome, depending on the
cohort. Similar models were also estimated for referrals
and CIN 1þ results where the number of previous refer-
rals and CIN 1þ results (classified as 0 or 1þ) were
controlled for, respectively. Probabilities of the first
experienced event with 95% confidence intervals in
5-year age groups were derived from the model predic-
tions. Cumulative curves were obtained by subtracting
the cumulative probability of not experiencing the event
at ages 30–64 from unity.14 Program R (version 3.2.3)15
was used with packages geepack16 and doBy.17
Results
The screening profile of the study cohort (women born
between 1951 and 1965) is shown in the flowchart, with dif-
ferent pathways leading to follow-up screening (Figure 1).
The total number of invitations and visits are shown sep-
arately for routine and follow-up screens. The screening
results of routine screens are shown on the upper part of
the figure (white background). Average attendance rate
was 74%. Among the 1,207,017 screens, 94% were
normal, 6% borderline, and 0.7% resulted in referral to
colposcopy. Of the normal screening results, 3% led to a
follow-up screen within the same 5-year screening round
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during 4 years. Of these, 96% were women reporting signs
of symptoms. The proportions of borderline and referral
results leading to follow-up screening were 73% and 44%,
respectively.
An individual might have received as many as four
follow-up screens within the same 5-year screening
round. Multiple follow-up screens occurred if the
woman repeatedly reported symptoms, but no abnormal-
ities warranting referral were detected by the screening
test. However, the majority (>76%) of the women being
followed up had only one follow-up screening before the
next round, in which either a negative or a positive result
was confirmed. Attendance to follow-up screening was
better among women whose routine screening result was
Figure 1. Flowchart of screening outcomes during 1991–2012 among the study cohorts: Routine screening (white background) and
different pathways to follow-up screening (grey background).
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normal than among those with borderline or referral rou-
tine results (Figure 1).
Table 1 shows the number of women in the three study
cohorts, separately and combined, invited to cervical
screening between 1991 and 2012. Around 93% of the
women participated at least once. The proportion of
women who underwent 1–5 screens and had at least one
borderline result during the study period was 17%.
Proportions of referrals and CIN 1þ results were much
lower (<2%). The overall proportion of women experien-
cing more than one abnormality of any kind was 2.7%,
varying between 2.5% and 2.9% in the sub-cohorts.
Multiple referrals and CIN 1þ results were very uncom-
mon (0.07% and 0.01%, respectively). Invitations were
sent irregularly to 11% of the women. Further, 53% of
women did not attend all routine screens to which they
were invited, and therefore had less than five screens
during the follow-up period. Irregular attendance was
more common in the younger cohorts (Table 1).
The cumulative probabilities of any abnormality in the
study cohorts were approximately 25–30% after 20 years
of follow-up, the proportion being larger for younger
cohorts (Figure 2a–c). The probabilities for a referral
and a CIN 1 or more severe result were approximately
3–5% and 1–2%, respectively, again younger cohorts
having larger probabilities. Thus, the proportion of bor-
derline results without a more severe diagnosis was more
than 20% for all cohorts. Younger women were more
likely to have any abnormality, with the risk starting to
decrease around age 45 (Figure 2a–c). The probability of
experiencing any abnormality at ages 30–64 was nearly
34.0% (95% CI: 33.3–34.7%) (Figure 2d). The proportion
of borderline only, without a more severe result, was
nearly 30%. Results warranting referral and results with
CIN 1þ accumulated to 5.4% (95% CI: 5.0–5.8%) and
2.2% (95% CI: 2.0–2.4%), respectively. Thus, the prob-
ability of experiencing a referral without a histologically
confirmed finding, by the age of 64 was approximately
3%. The risk of any abnormality began to decline after
age 45 in all cohorts (Table 2). Abnormalities at least war-
ranting referral decreased quite linearly through age.
Previous occurrences were associated with an increased
risk, specifically in older cohorts. The effect was stronger
if there were more than one previous abnormality of any
kind, with an odds ratio of 3.79 (95% CI: 3.45–4.17) in the
oldest cohort. If there were irregularities in the invitation
and/or attendance histories, the risk of any abnormality
was slightly elevated. Irregular attendance history was
also associated with an increased risk of referral and
CIN 1þ results, but no effect was observed with invita-
tional irregularities (Table 2).
Discussion
According to our results, the cumulative probability of
any abnormality detected by the Finnish organized screen-
ing programme was, on average, 34% by age 64, for
women starting screening in their 30s. The difference in
the magnitude between mild and more severe results was
substantial, the cumulative probability of results









Screened at least once 92.7 (364 487) 92.5 (56 800) 92.8 (143 530) 92.6 (164 157)
One or morea
Any abnormality 19.1 (69 687) 19.3 (10 949) 19.9 (28 498) 18.4 (30 240)
Referral or more severe 2.6 (9 501) 2.9 (1 642) 2.9 (4 085) 2.3 (3 774)
CIN1 or more severe 1.0 (3 657) 1.4 (766) 1.1 (1 583) 0.8 (1 308)
Borderline 17.1 (62 239) 17.0 (9 633) 17.6 (25 280) 16.7 (27 326)
Referral with normal histology 1.6 (5 795) 1.5 (866) 1.7 (2 469) 1.5 (2 460)
CIN 1 0.3 (1 173) 0.4 (237) 0.3 (481) 0.3 (455)
CIN 2 0.3 (1 086) 0.4 (238) 0.3 (486) 0.2 (362)
CIN 3 0.4 (1 282) 0.5 (279) 0.4 (556) 0.3 (447)
Cancer 0.0 (139) 0.0 (17) 0.1 (69) 0.0 (53)
Two or morea
Any abnormality 2.7 (9 922) 2.5 (1 411) 2.9 (4 169) 2.7 (4 342)
Referral or more severe 0.1 (253) 0.1 (33) 0.1 (109) 0.1 (111)
CIN 1 or more severe 0.0 (34) 0.0 (7) 0.0 (14) 0.0 (13)
Irregularitiesa
Invitation 10.6 (38 690) 9.8 (5 581) 8.9 (12 809) 12.4 (20 300)
Attendance 53.0 (193 316) 62.5 (35 474) 54.7 (78 485) 48.3 (79 357)
CIN: cervical intraepithelial neoplasia.
aProportions of screened women.
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warranting referral being 5%, and results of CIN 1þ 2%
in the programme. The incidence of borderline results in
Finland is higher than in many other countries, whereas
referrals to colposcopy and histologically confirmed CIN
1þ results are comparatively less frequent.8 When cumu-
lated over the long study period, these differences are
emphasized. There seems to be an imbalance in the diag-
nostic practice with an overemphasis on borderline
abnormalities.
The Finnish programme screens women using a 5-year
interval. Although this seems to detect a large amount of
mild abnormalities, the cumulative burden of abnormal
test results is also likely to be high in other countries,
especially if the screening interval is shorter than 5 years
and the number of lifetime screening rounds is high.5,18,19
The risk of developing high-grade CIN is elevated
for women with mild cervical abnormalities.2,20
Nevertheless, excessive detection of low-grade abnormal-
ities may result in unnecessary follow-up testing, which in
turn has a negative effect on the cost-effectiveness of
screening. From an individual woman’s perspective,
receiving information on an abnormal screening result
that requires follow-up testing causes adverse psycho-
logical effects of distress and anxiety.5,7
The use of secondary HPV testing in addition to con-
ventional cytology or primary HPV testing with cytology
triage in women with borderline results could improve the
specificity of referral to colposcopy and recommendations
for follow-up screens.21,22 However, HPV testing appears
to perform best among women aged 35 or older, and has a
poorer specificity than conventional cytology among
younger women.23,24 Secondary HPV testing has not
been used extensively in Finland. During the study
period, primary HPV testing with cytology triage has
been used in a large randomized implementation study
since 200310,25 and, according to information at the
Mass Screening Registry, in a large municipality starting
primary HPV screening in 2012.
We chose CIN 1 or a more severe histologically
confirmed lesion as an outcome, indicating at least
Figure 2. Cumulative probabilities of the first occurrence of any abnormality (borderlineþ), referral and CIN 1þ results by age in the three
birth cohorts (a–c) and in all cohorts combined (d). Adjusted with irregular invitation / attendance history.
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mild dysplasia. Since 2010 the Finnish guidelines recom-
mended that, in general, CIN 1 should be managed with
surveillance. Thus, a clinically more meaningful outcome
currently would be CIN 2þ. During earlier years of the
follow-up, however, all cervical lesions (CIN 1þ) were
treated in Finland. In addition, by choosing CIN 1 as
the cut-off, we were able to quantify the so-called false
positive screens, i.e. colposcopy referrals where histologi-
cally confirmed lesions were not detected.
There is some variation between the municipalities in
practices concerning the implementation of national
guidelines for follow-up criteria. It has been reported
that large variation existed between cytopathology labora-
tories in the rates of follow-up recommendations and
referrals, although this was not shown to have an
impact on the effectiveness of screening.26 According to
national guidelines, borderline results should always be
followed up with an intensified frequency. We reported
that only 73% of the borderline results led to recommen-
dation for follow-up screening, suggesting that not all
municipalities followed the guidelines. This means that
the costs of the intensified follow-up practice could poten-
tially be higher than currently. Of the normal routine
screening results, 3% resulted in a follow-up recommen-
dation due to symptoms reported by the woman. In this
group it was more common to receive multiple follow-up
invitations during the same 5-year screening round. Since
2009 the symptom-based follow-up recommendations
have changed, and are now more conservative: only vagi-
nal bleeding after sexual intercourse is considered for
follow-up. Symptom-based follow-up testing within the
programme is therefore expected to decrease in the future.
Recurrent abnormalities, diagnosed during several
rounds for the same woman, were quite rare, even
though women experiencing abnormalities once were at
greater risk of experiencing subsequent ones. The effect
seemed to be more pronounced in older than in younger
women, and a similar trend was seen in all outcomes stu-
died. Persistent HPV infections have been shown to be
more prominent among older women.27,28 Our results
indicate that although fewer abnormalities are detected
among older women, the risk of recurrent abnormalities
increases with age. Previous research has supported the
screening of women above the currently recommended
target ages.29 It may also be worthwhile to monitor abnor-
mal recurrences, especially at older ages, as a persistent
HPV infection is a strong risk factor of progression to a
higher grade lesion.
Our results are based on extensive nationwide data with
a 22-year follow-up, with valid information on follow-up
procedures and diagnostic findings following the routine
screen. However, the numbers reported here are based on
the Mass Screening Registry, which contains only data on
the organized screening programme. Abnormalities
detected outside the programme are not included in the
analysis, as opportunistic Pap testing was not registered
centrally during the study period. In addition, a large pro-
portion of CIN 1þ cases are detected in women under
the screening ages, solely by opportunistic testing.30
Opportunistic activity also affects age groups targeted by
the organized programme, as additional tests are per-
formed even between the organized screens. Therefore,
the true cumulative proportion of referrals and CIN 1þ
cases for the target screening ages is likely to be higher
than reported here.31 Also, it is possible that variation
exists in the diagnostic criteria between organized and
opportunistic screening. To elaborate the results in
future studies we have started to incorporate opportunis-
tic data in the analysis. In this study, however, we were
specifically interested in the differences between the
Table 2. Odds ratios (95% confidence intervals) for the probability
of an occurrence of any abnormality (borderlineþ), referral, and
CIN 1þ in the three birth cohorts.
Any abnormality Referral CIN 1þ
1961–1965 cohort
Age
35 1.14 (1.07–1.20) 0.88 (0.76–1.02) 0.88 (0.72–1.08)
40 1.07 (1.00–1.13) 0.76 (0.65–0.89) 0.69 (0.55–0.86)
45 1.03 (0.97–1.09) 0.83 (0.71–0.97) 0.64 (0.51–0.81)
50 0.79 (0.73–0.87) 0.61 (0.48–0.77) 0.32 (0.21–0.48)
Previous occurrence
1 1.75 (1.64–1.86)
1 or more 2.03 (1.43–2.88) 2.03 (0.96–4.29)
2 or more 2.61 (2.17–3.15)
Irregular history
Invitation 1.31 (1.21–1.42) 1.02 (0.80–1.30) 0.71 (0.46–1.08)
Attendance 1.13 (1.08–1.17) 1.31 (1.17–1.47) 1.40 (1.18–1.67)
1956–1960 cohort
Age
40 1.17 (1.14–1.21) 0.99 (0.91–1.08) 0.94 (0.82–1.07)
45 1.07 (1.03–1.11) 0.78 (0.71–0.85) 0.60 (0.51–0.70)
50 0.83 (0.80–0.86) 0.83 (0.76–0.92) 0.45 (0.38–0.53)
55 0.54 (0.51–0.57) 0.54 (0.46–0.62) 0.24 (0.18–0.32)
Previous occurrence
1 1.93 (1.86–2.00)
1 or more 2.79 (2.28–3.40) 2.64 (1.53–4.56)
2 or more 3.10 (2.80–3.43)
Irregular history
Invitation 1.19 (1.12–1.26) 1.07 (0.91–1.27) 1.06 (0.78–1.44)
Attendance 1.12 (1.09–1.15) 1.27 (1.18–1.36) 1.61 (1.43–1.82)
1951–1955 cohort
Age
45 1.09 (1.06–1.12) 0.94 (0.85–1.03) 0.80 (0.69–0.92)
50 0.85 (0.82–0.87) 0.79 (0.71–0.86) 0.49 (0.41–0.57)
55 0.53 (0.51–0.55) 0.79 (0.72–0.87) 0.39 (0.33–0.47)
60 0.34 (0.32–0.36) 0.51 (0.44–0.59) 0.30 (0.23–0.39)
Previous occurrence
1 2.09 (2.02–2.17)
1 or more 3.7 (3.05–4.49) 3.84 (2.22–6.64)
2 or more 3.79 (3.45–4.17)
Irregular history
Invitation 1.15 (1.09–1.22) 1.02 (0.88–1.18) 0.79 (0.58–1.09)
Attendance 1.14 (1.11–1.17) 1.36 (1.26–1.48) 1.69 (1.47–1.95)
CIN: cervical intraepithelial neoplasia.
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cumulative probabilities of the three outcomes. We do not
expect the overall patterns in these differences to change
meaningfully, even after taking into account CIN diag-
noses between the organized screens. It is also noteworthy
that women who receive a referral after an opportunistic
Pap test are entitled to have their colposcopy and treat-
ment within the same public healthcare system as women
who are referred within the organized programme.
An individual woman’s lifetime risk of having screen-
detected mild abnormalities is strikingly high in our data.
The presented estimates are, in fact, conservative, as the 5-
year screening interval is comparatively long, and no
opportunistic screening is taken into account. An abnor-
mal screening result in itself cannot be considered as a
harm, but the handling of these abnormalities can poten-
tially be harmful if follow-up tests and treatment are
assigned where they are not needed.
Re-evaluation and improvement of diagnostic criteria
concerning borderline abnormalities may reduce the over-
diagnosis. Moreover, women with recurrent abnormal-
ities, especially at older ages, should be monitored well,
as they are at a greater risk of disease progression. Our
analysis can serve as a benchmark for assessing harms of
cervical cancer screening from an individual woman’s
perspective.
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9. Anttila A, Pukkala E, Söderman B, et al. Effect of organised screening on
cervical cancer incidence and mortality in Finland, 1963–1995: recent increase
in cervical cancer incidence. Int J Cancer 1999; 83: 59–65.
10. Anttila A, Hakama M, Kotaniemi-Talonen L, et al. Alternative technologies in
cervical cancer screening: a randomised evaluation trial. BMC Public Health
2006; 6: 1–8.
11. Liang K-Y and Zeger SL. Longitudinal data analysis using generalized linear
models. Biometrika 1986; 73: 13–22.
12. Xue X, Gange SJ, Zhong Y, et al. Marginal and mixed-effects models in the
analysis of human papillomavirus natural history data. Cancer Epidemiol
Biomarkers Prev 2010; 19: 159–169.
13. Twisk JWR, Smidt N and de Vente W. Applied analysis of recurrent events: a
practical overview. J Epidemiol Community Health 2005; 59: 706–710.
14. Gelfand AE and Wang F. Modelling the cumulative risk for a false-positive
under repeated screening events. Stat Med 2000; 19: 1865–1879.
15. R Core Team. R: A Language and Environment for Statistical Computing.
Vienna, Austria: R Foundation for Statistical Computinghttps://www.R-pro
ject.org/ (2015, accessed 2 March 2016).
16. Højsgaard S, Halekoh U and Yan J. The R package geepack for generalized
estimating equations. J Stat Softw 2006; 15: 1–11.
17. Højsgaard S and Halekoh U. doBy: Groupwise Statistics, LSmeans, Linear
Contrasts, Utilities. https://CRAN.R-project.org/package=doBy (2015,
accessed 2 March 2016).
18. Anttila A, von Karsa L, Aasmaa A, et al. Cervical cancer screening policies and
coverage in Europe. Cerv Cancer Screen Eur Union 2009; 45: 2649–2658.
19. Stout NK, Goldhaber-Fiebert JD, Ortendahl JD, et al. Trade-offs in cervical
cancer prevention: Balancing benefits and risks. Arch Intern Med 2008; 168:
1881–1889.
20. Holowaty P, Miller AB, Rohan T, et al. Natural history of dysplasia of the
uterine cervix. J Natl Cancer Inst 1999; 91: 252–258.
21. Denise Zielinski G, Snijders PJF, Rozendaal L, et al. High-risk HPV testing in
women with borderline and mild dyskaryosis: long-term follow-up data and
clinical relevance. J Pathol 2001; 195: 300–306.
22. Rebolj M, Bais AG, van Ballegooijen M, et al. Human papillomavirus triage of
women with persistent borderline or mildly dyskaryotic smears: comparison of
costs and side effects of three alternative strategies. Int J Cancer 2007; 121:
1529–1535.
23. Cuzick J, Sasieni P, Davies P, et al. A systematic review of the role of human
papilloma virus (HPV) testing within a cervical screening programme: sum-
mary and conclusions. Br J Cancer 2000; 83: 561–565.
24. Leinonen M, Nieminen P, Kotaniemi-Talonen L, et al. Age-specific evaluation
of primary human papillomavirus screening vs conventional cytology in a
randomized setting. J Natl Cancer Inst 2009; 101: 1612–1623.
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